Wedbush Downgrades Blueprint Medicines (BPMC) to Neutral
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded Blueprint Medicines (NASDAQ: BPMC) from Outperform to Neutral with a price target of $129.00 (from $128.00).
For an analyst ratings summary and ratings history on Blueprint Medicines click here. For more ratings news on Blueprint Medicines click here.
Shares of Blueprint Medicines closed at $101.35 yesterday.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Chemtrade Logistics Income Fund (CHE-U:CN) (CGIFF) PT Raised to Cdn$18.50 at Desjardins
- Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
